

WE CLAIM:

1. A method of creating an immune privileged site wherein said method comprises administering RPE cells in an amount effective to create an immunologically privileged site.

2. A method of treating a disease in a mammal wherein said method comprises administering RPE cells that supply a therapeutic protein or biologically active molecule to a mammal in need of said treatment, wherein said RPE cells are administered in an amount effective to create an immunologically privileged site and sustain a therapeutic effect.

3. A method of treating a disease in a mammal wherein said method comprises co-administering of RPE cells with cells that supply a therapeutic protein or other biologically active molecule, wherein said RPE cells are administered in an amount effective to create an immunologically privileged site and cells that supply a therapeutic protein or other biologically active molecule are administered in an amount effective to sustain a therapeutic effect.

4. The method of Claim 2 or 3 wherein said therapeutic protein or other biologically active molecule consist of a growth factor, cytokine, hormone, peptide fragment of a hormone, inhibitor of cytokines, peptide growth or differentiation factor, interleukin, chemokine, interferon, neurotransmitter, colony stimulating factor or angiogenic factor.

5. The method of Claim 3 wherein said cells that produce said therapeutic molecule are cells transformed by a nucleic acid encoding said therapeutic protein or other biologically active molecule.

a
c 6. The method of Claim 1, 2 or 3 wherein the RPE cells, or the co-administered ^{Second} cells, are attached to a matrix prior to administration.

a 5 7. The method of Claim 1, 2 or 3 wherein said administering is by transplantation.

a 8. The method of Claim 2 wherein the RPE cells are transformed by a nucleic acid encoding said therapeutic protein or other biologically active molecule.

a 9. The method of Claim 1, 2 or 3 wherein said RPE cells are administered in a dose ranging from 10^3 to 10^7 cells.

15 C 10. The method of Claim 3 wherein said ^{Second} cells that produce said biological factor are administered in a dosage of from 10^3 to 10^7 cells.

C 20 11. The method of Claim 7 wherein said transplantation is by xenograft.

C 12. The method of Claim 7 wherein said transplantation is by allograft.

a 25 13. The method of Claim 2 or 3 wherein the disease consists of a neurological, cardiac, endocrine, hepatic, pulmonary, metabolic or immunological disease.

a 30 14. The method of Claim 1, 2 or 3 wherein the RPE cells are re-administered in an effective amount to sustain an immunologically privilege site.

a 35 15. The method of Claim 2 or 3 wherein the RPE cells, or co-administered cells that supply the therapeutic protein or other biologically active molecule are re-administered in an effective amount to sustain a therapeutic effect.

Subt A2
5 ~~16. A pharmaceutical composition comprising RPE cells and cells that produce a therapeutic protein or other biologically active molecule and a pharmaceutically acceptable carrier.~~

~~17. A pharmaceutical composition comprising RPE cells attached to a matrix.~~

Subt A3
10 ~~18. A pharmaceutical composition comprising RPE cells and cells that produce a therapeutic protein, or other biologically active molecule, are attached to a matrix.~~

15 19. The composition of Claim 16 wherein therapeutic protein, or other biologically active molecule consists of a growth factor, cytokine, hormone, peptide fragment of a hormone, inhibitor of cytokines, peptide growth or differentiation factor, interleukin, chemokine, interferon, colony stimulating factor or angiogenic factor.

20 ~~20. A pharmaceutical composition comprising RPE cells and a pharmaceutically acceptable carrier.~~

Sub C5
25 ~~21. A compartmentalized kit adapted to receive a first container adapted to contain RPE cells and a second container adapted to contain cells that produce a therapeutic molecule that is absent or defective in a disease.~~

30 ~~22. A compartmentalized kit adapted to receive a first container adapted to contain RPE cells and a second container adapted to contain pancreatic islet of Langerhans cells.~~

Subt A4
35 ~~23. An article of manufacture comprising a packaging material and RPE cells contained within said packaging material, wherein said RPE cells are effective for creating an immunologically privileged site in a mammal, and wherein said packaging material contains a label that indicates that~~

